The approved anti-PD-1 and anti-PD-L1 antibodies blocking the axis PD-1 and PD-L1/PD-L2 have confirmed the immune system’s role in mediating the antitumor response, leading T cells to kill tumor cells (12). This evidence concerns the gene PDCD1LG2 and neoplasm.